Sanford guide Android version

Requirements: 8.0 and up
Overview: The Sanford Guide mobile app ($39.99/yr In-App subscription) includes all the information you’ve come to expect from our print guide with expanded digital-only content and numerous interactive features that make it an indispensable resources.

Since 1969 Sanford Guide has been the leading clinical reference for treatment of infectious diseases. Popular with physicians pharmacists physician assistants nurse practitioners and other clinicians Sanford Guide provides medical information that is convenient concise and reliable. Coverage includes: clinical syndromes (organized by anatomic system/site of infection) pathogens (bacterial fungal mycobacterial parasitic and viral) anti-infective agents (dosing adverse effects activity pharmacology interactions) expanded HIV/AIDS and Hepatitis information specialized dosing tables and tools calculators and preventative therapy all evidence-based and extensively referproces

More about auto-renewing subscriptions to Sanford Guide:
-An in-app subscription is one year for $39.99.
-Payment will be charged to your Google Play Account at confirmation of purchase.
-Subscriptions automatically renew unless auto-renew is turned off at least 24-hours before the end of the current subscription period.

-Your Google Play Account will be charged for renewal within 24-hours prior to the end of the current subscription period.

-Subscriptions may be managed by the user and auto-renewal may be turned off by going to the user’s Account Settings after purchase.
-No cancellation of a current subscription is allowed during the active subscription period.
-Subscriptions are subject to our Terms of Use which are available at: http://www.sanfordguide.com/about/legal/terms-of-use/.

Instructions:

On the first launch, for a better experience (to unlock paid content), please sign in. If you see any purchase banners, you can ignore them because all content is already unlocked.

After a successful login, navigate to "Account" and tap on "Force Content Download." This action will install all the paid content.

To access addon packages, go to the "Regional Guidelines" section on the home screen (under "GUIDE"). From there, you can download and access the available add-ons. (Some hidden add-ons are also listed (forced) Note: Paid add-ons will not work

Download

Mediafire

BNF for children 2022-2023 pdf version

Published jointly by the British Medical Association, Royal Pharmaceutical Society, the Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric Pharmacists Group.

The BNF for Children is the first choice for concise medicines information for children. Trusted by healthcare professionals across the world to support confident decision-making at the point of care.

The new edition provides up-to-date guidance on prescribing, dispensing, and administering medicines to children, plus legal and professional guidelines.

Recommendations in the BNF for Children have been constructed on the basis of authoritative sources, emerging evidence, best practice guidelines and advice from a network of paediatric experts. The process is overseen by a paediatric formulary committee.

Extensive content updates in the BNF for Children 2022-2023 edition include:

New monographs for:

• Acarizax® [house dust mite extract] for house dust mite allergic rhinitis
• Adakveo® [crizanlizumab] for vaso-occlusive crises in sickle-cell disease
• Cibinqo® [abrocitinib] for atopic eczema
• Dificlir® [fidaxomicin] for Clostridioides difficile infection
• Evrysdi® [risdiplam] for 5q spinal muscular atrophy
• Fintepla® [fenfluramine] for adjunctive therapy of seizures associated with Dravet syndrome
• Givlaari® [givosiran] for acute hepatic porphyria
• Keytruda® [pembrolizumab] for classical Hodgkin lymphoma
• Koselugo® [selumetinib] for inoperable plexiform neurofibromas in patients with neurofibromatosis type 1
• Liraglutide for weight management or type 2 diabetes mellitus
• Orladeyo® [berotralstat] for hereditary angioedema
• Pradaxa® [dabigatran etexilate] for prophylaxis or treatment of venous thromboembolism
• Rinvoq® [upadacitinib] for atopic eczema
• Ruconest® [conestat alfa] for hereditary angioedema in patients with C1-esterase inhibitor deficiency
• Ryaltris® [mometasone furoate with olopatadine] for allergic rhinitis
• Taltz® [ixekizumab] for plaque psoriasis
• Ultomiris® [ravulizumab] for atypical haemolytic uraemic syndrome or paroxysmal nocturnal haemoglobinuria
• Xarelto® [rivaroxaban] for prophylaxis or treatment of venous thromboembolism
• Xeljanz® [tofacitinib] for polyarticular juvenile idiopathic arthritis or juvenile psoriatic arthritis
• Xevudy® [sotrovimab] for COVID-19
• Xofluza® [baloxavir marboxil] for post-exposure prophylaxis or treatment of influenza

MHRA advice on:

• Adrenaline/epinephrine auto-injectors: reminder for prescribers to support safe and effective use
• Amiodarone hydrochloride (Cordarone X®): reminder of risks of treatment and need for patient monitoring and supervision
• Atezolizumab (Tecentriq®) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)
• Chloral hydrate, cloral betaine (Welldorm®): restriction of paediatric indication
• Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years
• Chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions
• Hydroxychloroquine sulfate: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions
• Ivacaftor, tezacaftor, elexacaftor (Kaftrio®▼) in combination with ivacaftor (Kalydeco®): risk of serious liver injury; updated advice on liver function testing
• Levothyroxine sodium: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products
• Metformin hydrochloride: study shows no safety concerns in pregnancy
• Oral retinoid medicines: temporary monitoring advice during COVID-19 pandemic
• Remdesivir: reporting to the UK COVID-19 Antivirals Pregnancy Registry
• Tofacitinib (Xeljanz®): new measures to minimise risk of major adverse cardiovascular events and malignancies
• Topical corticosteroids: information on the risk of topical steroid withdrawal reactions
• Yellow fever vaccine, live (Stamaril®): new pre-vaccination checklist

Other significant changes include updated guidance on:

• Aciclovir: important safety information added to highlight different approaches to calculating doses depending on the age of the child
• Management of acne
• Management of anaphylaxis
• Contraceptives, interactions
• COVID-19 updated guidance in-line with Public Health England/UK Health Security Agency recommendations, including reports of myocarditis and pericarditis with the Pfizer/BioNTech and Moderna vaccines and update to age range of Pfizer/BioNTech vaccine
• Diabetic hyperglycaemic emergencies
• Management of acute otitis media
• Emergency contraception
• Management of Clostridioides difficile infection
• Immunisation schedule updated guidance in-line with Public Health England/UK Health Security Agency recommendations, including Bacillus Calmette-Guérin, human papillomavirus, and influenza vaccines and immunisation of neonates
• Levetiracetam dosing added for convulsive status epilepticus in children
• Malaria prophylaxis in-line with Public Health England recommendations
• Miconazole oral gel no longer licensed for treatment of intestinal candidiasis
• Preventative migraine treatment
• Management of nausea and vomiting during pregnancy
• New guidance on management of neonatal bacterial infection
• Oral anticoagulants
• Paediatric Steroid Treatment Card to support early recognition and treatment of adrenal crisis in children with adrenal insufficiency [British Society for Paediatric Endocrinology and Diabetes]
• Chronic pain
• Phenobarbital oral solutions and advice from the RCPCH/NPPG
• Phosphate imbalance
• Potassium permanganate: inadvertent oral administration of potassium permanganate [National Patient Safety Alert advice]
• Prescribing in renal impairment
• Rabies vaccine and post-exposure management
• Remdesivir treatment duration
• Management of secondary bacterial infection of common skin conditions, including eczema
• Smoking cessation
• Tetanus vaccine and the use of immunoglobulin for tetanus infection and prophylaxis in-line with Public Health England recommendations
• Trientine dihydrochloride: name change to Trientine, and update to dosing for Wilson’s disease
• Recommended insulin regimens in type 1 diabetes
• Vitamin D

• Prescribing in renal impairment
• Rabies vaccine and post-exposure management
• Remdesivir treatment duration
• Management of secondary bacterial infection of common skin conditions, including eczema
• Smoking cessation
• Tetanus vaccine and the use of immunoglobulin for tetanus infection and prophylaxis in-line with Public Health England recommendations
• Trientine dihydrochloride: name change to Trientine, and update to dosing for Wilson’s disease
• Recommended insulin regimens in type 1 diabetes
• Vitamin D

BNF for Children 2022-2023 is an essential publication, it provides you with:

• Up-to-date information on prescribing, dispensing, and administering medicines
• Authoritative, independent guidance on best practice enabling you to select safe and effective medicines
• Information you know you can trust for quality, reliability, and independence
• Everything you need at your fingertips, all in one book

Download link:

Mediafire

BNF 83 pdf version

The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care.

The new edition (BNF 83) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines.

Extensive content updates in the BNF 83 edition include: 

New monographs for:

• Acarizax® [house dust mite extract] for house dust mite allergic rhinitis or house dust mite allergic asthma
• Adakveo® [crizanlizumab] for vaso-occlusive crises in sickle-cell disease
• Adtralza® [tralokinumab] for atopic eczema
• Bijuve® [estradiol with progesterone] for menopausal symptoms
• Evrenzo® [roxadustat] for symptomatic anaemia associated with chronic kidney disease
• Evrysdi® [risdiplam] for 5q spinal muscular atrophy
• Kesimpta® [ofatumumab] for multiple sclerosis
• Klisyri® [tirbanibulin] for actinic keratosis on face or scalp
• Lagevrio® [molnupiravir] for COVID-19
• Leqvio® [inclisiran] for primary hypercholesterolaemia or mixed dyslipidaemia
• Lumykras® [sotorasib] for non-small cell lung cancer with KRAS G12C mutation
• Ontozry® [cenobamate] for focal seizures with or without secondary generalisation
• Orladeyo® [berotralstat] for hereditary angioedema
• Pemazyre® [pemigatinib] for cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement
• Ponvory® [ponesimod] for multiple sclerosis
• Rukobia® [fostemsavir] for HIV drug-resistant infection
• Ryaltris® [mometasone furoate with olopatadine] for allergic rhinitis
• Ryeqo® [relugolix with estradiol and norethisterone acetate] for uterine fibroids
• Verquvo® [vericiguat] for chronic heart failure with reduced ejection fraction
• Zibor® [bemiparin sodium] for prophylaxis of deep-vein thrombosis in general and orthopaedic surgery, and prevention of clotting in extracorporeal circuits

MHRA advice on:

• Adrenaline/epinephrine auto-injectors: reminder for prescribers to support safe and effective use
• Aflibercept (Eylea®) solution for intravitreal injection: higher risk of intraocular pressure increase with the pre-filled syringe
• Atezolizumab (Tecentriq®) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)
• CDK4/6 inhibitors: reports of interstitial lung disease and pneumonitis, including severe cases
• Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years
• Dapagliflozin (Forxiga®) 5mg should no longer be used for the treatment of type 1 Diabetes Mellitus
• Levothyroxine sodium: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products
• Oral retinoid medicines: temporary monitoring advice during coronavirus (COVID-19) pandemic
• Tofacitinib (Xeljanz®): increased risk of major adverse cardiovascular events and malignancies with use of tofacitinib relative to TNF-alpha inhibitors, and new measures to minimise risk
• Topical corticosteroids: information on the risk of topical steroid withdrawal reactions
• Venetoclax (Venclyxto®): updated recommendations on tumour lysis syndrome (TLS) in chronic lymphocytic leukaemia (CLL) patients
• Yellow fever vaccine, live (Stamaril®): new pre-vaccination checklist

Other significant changes include updated guidance on:

• COVID-19 updated guidance in-line with Public Health England/UK Health Security Agency recommendations, including reports of myocarditis and pericarditis with the Pfizer/BioNTech and Moderna vaccines
• Advice on use of Dapagliflozin in renal impairment, including new indication for chronic kidney disease
• Diabetic hyperglycaemic emergencies
• Direct-acting oral anticoagulants
• Emergency contraception
• Malaria prophylaxis in-line with Public Health England recommendations
• Management of acne
• Management of acute coronary syndromes
• Management of anaphylaxis
• Management of secondary bacterial infection of common skin conditions
• Management of nausea and vomiting during pregnancy
• Prescribing in renal impairment
• Rabies vaccine and post-exposure management
• Recommended insulin regimens in type 1 diabetes
• Tetanus vaccine and the use of immunoglobulin for tetanus infection and prophylaxis in-line with Public Health England recommendations

BNF 83 is an essential publication, it provides you with:

• Up-to-date information on prescribing, dispensing, and administering medicines
• Authoritative, independent guidance on best practice enabling you to select safe and effective medicines
• Information you know you can trust for quality, reliability, and independence
• Everything you need at your fingertips, all in one book

Download link

Mediafire

BNF 80 pdf version

 

The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care. The new edition (BNF 80) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines.

The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care. The new edition (BNF 80) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines.

The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care. The new edition (BNF 80) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines.

The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care. The new edition (BNF 80) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines.

The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care. The new edition (BNF 80) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines.

Download link:

Mediafire

BNF 79 pdf

Compiled with the advice of clinical experts and continually updated to reflect the latest evidence from credible sources worldwide, the new edition of the British National Formulary 79 (BNF) provides up-to-date guidance on prescribing, dispensing, and administering medicines. Access to the latest edition of the BNF is vital for healthcare professionals, as it reflects current best practice as well as legal and professional guidelines relating to the uses of medicines. NICE has accredited the editorial process used by the British National Formulary to produce its resources.

Download:
Mediafire

The Sanford Guide to Antimicrobial Therapy 2018 – 48th edition

The 48th edition of the leading clinical reference on treatment of infectious diseases and anti-infective drug information will be released in late winter or early spring. Helpful in day-to-day practice and as a component of your organization’s antimicrobial stewardship program, the Sanford Guide provides valuable guidance in the age of antibiotic resistance. Popular with physicians, pharmacists, physician assistants, nurse practitioners, and other clinicians, the Sanford Guide to Antimicrobial Therapy provides information that is convenient, concise, and reliable.

Download:

Mediafire

BNF 78

Compiled with the advice of clinical experts and continually updated to reflect the latest evidence from credible sources worldwide, the new edition of the British National Formulary 78 (BNF) provides up-to-date guidance on prescribing, dispensing, and administering medicines. Access to the latest edition of the BNF is vital for healthcare professionals, as it reflects current best practice as well as legal and professional guidelines relating to the uses of medicines.


Download
Mediafire